{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-012891","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.078305+00:00","generated_at":"2026-05-15T07:48:19.331781+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance","bullets":["Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.","GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.","Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).","Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.","Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-012891","json":"https://secwatch.observer/filing/0001140361-26-012891.json","markdown":"https://secwatch.observer/filing/0001140361-26-012891.md","text":"https://secwatch.observer/filing/0001140361-26-012891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/ef20069681_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:48:19.331781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"acc9aa6442e0e686fd5bc05ab04d6b9e7f0a229d","claim":"ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.","evidence_excerpt":"the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal year 2026 ended February 28, 2026"},{"label":"Revenue","value":"$78.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}